Impaired lipolysis and dysregulated levels of circulating free fatty acids represent important causative factors for the development of insulin resistance, type 2 diabetes, cardiovascular disease and other hazardous metabolic conditions that rapidly advance and pose especially serious health risk in the elderly. Restraining metabolic diseases in the aging population will improve life quality as well as life expectancy and radically reduce health care costs. We have recently found that activation of mTORC1 inhibits expression of the rate-limiting lipolytic enzyme, ATGL, suppresses basal and cAMP-stimulated lipolysis, and causes marked accumulation of triglycerides in fat and muscle cells. Inhibition of mTORC1 has the opposite effect. In order to determine the molecular mechanism of mTORC1 action, we have conducted a screen in S. cerevisiae. Results of this screen suggest that mTORC1 inhibits ATGL expression via transcription factors of the early growth response (Egr) family. Thus, in Specific Aim 1 we propose to mechanistically establish the role of Egr1/2 in mTORC1- mediated transcription of ATGL and lipolysis, and in Specific Aim 2 we will investigate the role of the mTORC1/Egr1/2 axis in the metabolic disease and aging. We believe that our work will help to establish the mTORC1-mediated pathway as a central controller of FFA homeostasis and dysregulation of this pathway - as a major etiological factor of metabolic disease that limit healthspan and lifespan of the US population.

Public Health Relevance

Dysregulation of lipolysis in fat tissue represents a major causative factor for the development of cardiovascular disease, insulin resistance, and other age-related hazardous metabolic conditions. We have recently found that the mTORC1-mediated pathway controls lipolysis in adipocytes, and we propose to determine the molecular mechanism and the physiological significance of our observations.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AG039612-02
Application #
8328642
Study Section
Molecular and Cellular Endocrinology Study Section (MCE)
Program Officer
Finkelstein, David B
Project Start
2011-09-15
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2014-08-31
Support Year
2
Fiscal Year
2012
Total Cost
$245,550
Indirect Cost
$95,550
Name
Boston University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Singh, Maneet; Kaur, Rajween; Lee, Mi-Jeong et al. (2014) Fat-specific protein 27 inhibits lipolysis by facilitating the inhibitory effect of transcription factor Egr1 on transcription of adipose triglyceride lipase. J Biol Chem 289:14481-7
Huang, Guanrong; Buckler-Pena, Dana; Nauta, Tessa et al. (2013) Insulin responsiveness of glucose transporter 4 in 3T3-L1 cells depends on the presence of sortilin. Mol Biol Cell 24:3115-22
Chakrabarti, Partha; Kim, Ju Youn; Singh, Maneet et al. (2013) Insulin inhibits lipolysis in adipocytes via the evolutionarily conserved mTORC1-Egr1-ATGL-mediated pathway. Mol Cell Biol 33:3659-66